PULSE BIOSCIENCES, INC. 8-K/A

What Happened

Pulse Biosciences, Inc. (PLSE) filed a Form 8-K (filed March 2, 2026) reporting that Kevin P. Danahy, the company's Chief Commercial Officer, gave notice of his immediate resignation effective February 27, 2026. The filing was made under Item 5.02 (Departure of Directors or Certain Officers).

Key Details

• Kevin P. Danahy, Chief Commercial Officer, resigned effective February 27, 2026.
• The 8-K reporting the departure was filed on March 2, 2026.
• The filing includes an Inline XBRL cover page exhibit (Item 9.01, Exhibit 104).
• No replacement or additional details about the reason for resignation were provided in the 8-K.

Why It Matters

Executive departures can affect a company’s commercial leadership and go-to-market execution. For investors, this is a material executive change to note for Pulse Biosciences’ management stability and commercial strategy; however, the 8-K does not disclose financial impacts, severance, or a successor. Monitor subsequent filings or company announcements for plans to fill the CCO role and any commentary on potential effects to sales, revenue guidance, or commercialization efforts.